{"disease":{"id":"locally-advanced-unresectable-esophageal-squamous-cell-carcinoma","name":"locally advanced unresectable esophageal squamous cell carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT07530094","title":"Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":98,"lead_sponsor_name":"Ning Jiang, M.D./Ph.D.","has_results":false},{"nct_id":"NCT06265285","title":"Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT07112833","title":"A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Hebei Medical University Fourth Hospital","has_results":false},{"nct_id":"NCT07435454","title":"Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":22,"lead_sponsor_name":"Jiangsu Cancer Institute & Hospital","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}